Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Zhensheng Li *, Dongxing Shen, Jian Zhang, Jun Zhang, Fang Yang, Deyou Kong, Jie Kong and Andu Zhang

Abstract

Background: The relationship between whole brain radiotherapy (WBRT) dose with intracranial tumor control and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) is largely unknown.

Methods: We retrospectively analyzed 595 NSCLC BM patients treated consecutively at the Fourth Hospital of Hebei Medical University between 2013 to 2015. We assigned the patients into 4 dose groups of WBRT: none, < 30, 30–39, and ≥ 40 Gy and assessed their relationship with OS and intracranial progression-free survival (iPFS). Cox models were utilized. Covariates included sex, age, KPS, BM lesions, extracranial metastasis, BM and lung tumor resection, chemotherapy, targeted therapy, and focal radiotherapy modalities.

Results: Patients had a mean age of 59 years and were 44% female. Their median survival time (MST) of OS and iPFS were 9.3 and 8.9 months. Patients receiving none (344/58%), < 30 (30/5%), 30–39 (93/16%), and ≥ 40 (128/22%) Gy of WBRT had MST of OS (iPFS) of 7.3 (6.8), 6.0 (5.4), 10.3 (11.9) and 11.9 (11.9) months, respectively. Compared to none, other WBRT groups had adjusted HRs for OS - 1.23 (p > 0.20), 0.72 (p = 0.08), 0.61 (p < 0.00) and iPFS - 1.63 (p = 0.03), 0.71 (p = 0.06), 0.67 (p < 0.01). Compared to 30–39 Gy, WBRT dose ≥40 Gy was not associated with improved OS and iPFS (all p > 0.40). Stratified analyses by 1–3 and ≥ 4 BM lesions and adjustment analyses by each prognostic index of RPA class, Lung-GPA and Lung-molGPA supported these relationships as well.

Conclusions: Compared to none, WBRT doses ≥30 Gy are invariably associated with improved intracranial tumor control and survival in NSCLC BM patients.

Keywords: Whole brain radiotherapy, Non-small cell lung cancer, Brain metastases, Overall survival, Intracranial progression-free survival

Background

Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), affecting up to 50% of patients within the overall disease course [1, 2]. Even with the best supportive care, BM patients usually have a median survival time (MST) of only 1–2 months [3]. The BM population is extremely heterogeneous with varied outcomes significantly associated with the recursive partitioning analysis (RPA) classes I - III and graded prognostic assessment (GPA) criteria scores [4–6]. For decades, whole brain radiotherapy (WBRT) to control neurologic symptoms and intracranial tumor growth has been the standard treatment for NSCLC BM patients [7, 8]. In some studies, WBRT has been shown to extend patient MST up to 7 months with a range of 3 to 15 months [5, 8]. However, the relationship between total or biological effective dose (BED) of WBRT with intracranial tumor control and overall survival (OS) has not been elucidated well [9].
Supported mostly by symptom control trials, current NCCN guidelines (version.2.2018) recommend WBRT dose schemes of 20 - 40Gy/5–20 fractions (f) and 20Gy/5f for poor responders [10–13]. For patients who are oligometastatic (having 1–3 lesions) or have good GPA scores, WBRT is combined with surgical resection or stereotactic radiotherapy (SRT) to further reduce intracranial relapse and mortality [14–17]. For patients with multiple metastases (having ≥4 lesions), WBRT is preferably used; however, intensity of WBRT has severe side effects of dose-related memory decline and neurocognitive dysfunction over time should be considered when considering treatment dosage [18–21]. To resolve this dilemma, radiosensitizing or chemotherapeutic agents and hippocampal avoidance techniques have been studied in pursuit of the optimal low but still effective WBRT dose [22–25]. In this regard, the determination of minimal WBRT dose for tumor control or survival improvement is highly relevant.

This study assesses the association of WBRT total dose levels with OS and intracranial progression-free survival (iPFS) through retrospective analysis of a recent cohort of NSCLC BM patients treated at one center in China.

**Methods**

**Study population**

Five hundred ninety-five NSCLC BM patients who were newly and consecutively treated at the Fourth Hospital of Hebei Medical University between 2013 to 2015 were retrospectively considered and analyzed in our study. All patients received a pathological diagnosis of NSCLC based on the primary tumor and their BM diagnoses were established by CT or MRI brain imaging. Meningeal metastasis was additionally diagnosed by having imaging features of enhanced nodules or lumps of BM images or malignant cells identified in the cerebrospinal fluid. Patients were followed up every 2 to 3 months after discharge and encouraged to visit the hospital clinic immediately upon new or worsening signs or symptoms. Patients alive on December 1, 2016 were censored. Treatment failures included death or intracranial tumor progression defined as a new enhancing lesions or > 20% increase in one-dimensional measurements of an existing lesion per the Response Evaluation Criteria in Solid Tumor (RECIST) guidelines (version 1.1). The OS (iPFS) days was defined as 1 plus number of days between BM diagnosis and death date (the earlier date of treatment failures) or December 1, 2016, whichever was earliest. iPFS was considered as a proximate measure of intracranial tumor control.

**WBRT and other radiotherapy on BM**

Only 42% (n = 251) of our study population received WBRT regardless of other RT modalities administered. Causes could be admissions and management in different clinical departments of our hospital independent of consultation with the Department of Radiation Oncology as well as some physicians lacking standardized guidelines to treat NSCLC BM.

In consideration of variable independence required in statistical models, RT modalities were classified into (1) four total dose levels of WBRT: 0 (i.e. none), < 30, 30–39, and ≥ 40 Gy; (2) three local RT dose levels of 0, < 50, and ≥ 50 Gy delivered focally or through boost RT with simultaneous or sequential WBRT to the largest BM lesion; (3) whether SRT was used or not.

All RTs were delivered with 3-dimensional conformal or intensity-modulated ones (IMRT) and used 6 MV X-rays generated by medical accelerators. Only daily RT was performed. Among WBRT patients, the delivered regimens of 40Gy/20f, 30Gy/10f, and 37.5Gy/15f constituted 46, 41, and 5% (n = 12), respectively; less than 3% (n = 6) selectively used 20Gy/5f due to initial poor performance; less than 6% failed to complete the prescribed WBRT sessions due to debilitating performance, serious adverse events (SAEs), or voluntary withdrawal. Further analysis of charted SAE events showed that over 95% SAEs were hematologic in nature (leukopenia, neutropenia, or thrombocytopenia) with Radiation Therapy Oncology Group (RTOG) toxicity grades ≥3, likely due to recent chemotherapy or chest RT. All SRTs were carried out with Gamma Knife with marginal doses of 10–15 Gy (defined to represent the 50% prescription isodose line) to the solitary or larger tumor of BM patients with 1–2 brain lesions.

**Statistical methods**

Statistics were described in terms of mean, median, percentage of total, standard deviation (std), and others. Comparisons were conducted by ANOVA, Wilcoxon rank-sum, Chi-squared test or Fisher’s Exact test if applicable. Kaplan-Meier curves were used to estimate MSTs and 95% confidence intervals (CI). Proportional hazard Cox models were used to estimate hazard ratios (HR) and 95% CIs with p values. Final covariates were determined after examining univariate analysis results and through review of current literature. Two-sided p < 0.05 was cited as being statistically significant. All statistical analyses were performed with SAS 9.20.

**Ethics and Informed consent.**

The study was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University in China in 2016 (record #: 2016–0634). No written or verbal consent from participants was needed for retrospective analyses under the Chinese Government’s medical research regulation and restrictions. Only de-identified protected health information was used.
Results

Comparison of patient’s characteristics among WBRT subgroups

Overall, patients had a mean age (std, range) of 58.7 (10.0, 27–82) years. 43.5% were female; 42% (n = 251) had WBRT. Patients were stratified into four dose levels of WBRT as mentioned previously, 0 (i.e. none), <30, 30–39, and ≥40 Gy, with compositions (number) of 58% (344), 5% (30), 16% (93) and 22% (128), respectively (Table 1). In short, patients who had WBRT were more likely to have poor performance (Karnofsky Performance Score, KPS < 70), short NSCLC history (<1 month), no extracranial metastases, radical resection of primary lung tumor, and were less likely to have de novo cTNM Stage IV (60% vs. 80%) at NSCLC diagnosis.

Survivals of overall and by WBRT subgroups

Overall, the estimated MST (95% CI) of OS and iPFS were 9.3 (8.3–10.0) and 8.9 (7.6–9.6) months. Figure 1 shows the Kaplan-Meier curves of OS and iPFS of the four WBRT dose groups (both log-rank test p < 0.001) 0, <30, 30–39, and ≥40 Gy. The MST of OS (iPFS) were 7.3 (6.8), 6.0 (5.4), 10.3(11.9) and 11.9 (11.9) months, respectively. Pair-wise comparisons showed non-WBRT patients had worse OS and iPFS than WBRT patients with doses of 30–39 Gy or ≥40 Gy (both p < 0.001). No statistical differences of OS and iPFS between patients with WBRT 30–39 Gy and ones with WBRT ≥40 Gy (both p > 0.50) were found. Estimated one-year survival rates were 37, 11, 62, and 63% for OS and 29, 11, 62, and 62% for iPFS, respectively.

Univariate and multivariable survival analyses

Table 2 shows the univariate analysis results. Except for SRT, cardiovascular disease (CVD), BM lesion number, BM resection, initial cTNM Stage IV, many characteristics were found to be statistically associated with OS or iPFS (p < 0.05). Compared to no treatment, WBRT 30–39 Gy and ≥40Gy were found to be significantly associated with improved OS or iPFS.

Table 3 shows the multivariable analysis results. Tumor pathology (adenocarcinoma vs. non-adenocarcinoma) was not included as a covariate because it was insignificantly associated with OS and iPFS, with adjusted HRs of 1.066 (p = 0.59) and 0.965 (p = 0.75), respectively. Compared to none, both WBRT 30–39 Gy and ≥40 Gy were associated with improved OS, with HRs of 0.722 (p = 0.08) and 0.609 (p < 0.01) respectively, and with improved iPFS, with HRs of 0.714 (p = 0.06) and 0.669 (p < 0.01) respectively. However, patients with WBRT ≥40 Gy and 30–39 Gy showed no significant difference of OS (HR 0.843, p = 0.34) and iPFS (HR 0.937, p = 0.70). If the dose-effect of WBRT is assumed to be in one direction and continuous, WBRT doses ≥30 Gy appear to be invariably associated with improved intracranial tumor control and survival in NSCLC BM patients. Compared to none, local RT dose ≥50 Gy and SRT were significantly associated with improved OS. Compared to none, the local RT dose ≥60 Gy was significantly associated with improved iPFS (p = 0.03).

The significantly worse iPFS (HR 1.625, p = 0.03) associated with WBRT < 30Gy (vs. none) was an unexpected finding. Uncorrected selective bias and or confounding effects by those unadjusted or uncollected covariates could exist. In addition, patients with WBRT < 30Gy (n = 30) either had WBRT 20Gy/5f (n = 6, all KPS < 60) or withdrew prior to completing the full WBRT with planned ≥30G dose due to the most commonly worsening KPS (related or unrelated to CNS symptoms). This observed association should be regarded as reverse correlation rather than causation. To the best of our knowledge, there are no published pathological mechanisms or studies supporting the role of WBRT accelerating the dying process. The dose-effect profile of WBRT under 30 Gy merits further investigation best in randomized controlled studies.

Stratified multivariable survival analyses by BM lesion number

To further examine if WBRT dose-effect survival profiles in oligometastatic patients could present differently from multiple metastatic ones, two sets of stratified multivariable survival analyses were conducted. Table 4 shows that WBRT 30–39 Gy and WBRT ≥40 Gy had no different effect on OS and iPFS in each subset of BM lesions (all p ≥ 0.50). Compared with the non-stratified analyses, smaller stratified analysis sizes generated slightly higher p values (p = 0.05–0.20) of WBRT 30–39 Gy with improved OS and iPFS (HR = 0.59–0.78) as compared to non-WBRT patients.

Adjustment survival analyses by common prognostic index

The RPA, Lung-GPA, and Lung-molGPA scores are user-friendly prognostic indice in NSCLC BM patients. Their calculation formula are reported in literature [6, 20]. Table 5 shows all three prognostic indices predicted OS well for our Chinese cohort. In addition, each adjustment model by prognostic index and RT modalities shows that WBRT 30–39 Gy and ≥40 Gy provided no statistically different HRs of OS (all p > 0.25). The same conclusion was reached for HRs of iPFS (data not shown). Thus, use of these prognostic indices as one integrated covariate supported the conclusions above as well.

Discussion

WBRT has been used as a standard treatment for BM patients for decades. However, the relationships of WBRT total dose with intracranial tumor control and
Table 1: Patient characteristics and their comparison among subgroups by WBRT dose

| Variables                  | WBRT Dose               | All       |
|----------------------------|-------------------------|-----------|
|                            | None (n₁ = 344)         | < 30Gy (n₂ = 30) | 30-39Gy (n₃ = 93) | ≥40Gy (n₄ = 128) | (N = 595) |
|                            | n(%) (N%)               | n(%) (N%) | n(%) (N%) | n(%) (N%) | p<sub>a</sub> |
| Sex female                 | 159 (46.2)              | 14 (46.7) | 30 (32.3) | 56 (43.8) | 0.114       | 259 (43.5) |
| male                       | 185 (53.8)              | 16 (53.3) | 63 (67.7) | 56 (56.2) | ns          | 336 (56.5) |
| CVD                        | 146 (42.4)              | 18 (60.0) | 40 (43.0) | 53 (41.4) | ns          | 257 (43.2) |
| Age (years)                |                         |           |           |           |             |           |
| <50                        | 61 (17.7)               | 3 (10.0)  | 13 (14.0) | 25 (19.5) | 0.115       | 102 (17.1) |
| 50–59                      | 104 (30.2)              | 8 (26.7)  | 36 (38.7) | 52 (40.6) | 200 (33.6)  |
| ≥ 60                       | 179 (52.6)              | 19 (63.3) | 44 (47.3) | 51 (39.8) | 293 (49.2)  |
| KPS < 70                   | 86 (25.0)               | 13 (43.3) | 37 (39.8) | 54 (42.2) | < 0.001     | 190 (31.9) |
| 70–80                      | 77 (22.4)               | 7 (23.3)  | 35 (37.6) | 45 (35.2) | 164 (27.6)  |
| ≥ 90                       | 181 (52.6)              | 10 (33.3) | 21 (22.6) | 29 (22.7) | 241 (40.5)  |
| NSCLC history (month)      |                         |           |           |           |             |           |
| < 1                        | 197 (57.2)              | 12 (40.0) | 41 (44.1) | 51 (39.8) | 0.004       | 301 (50.6) |
| 1–6                        | 45 (13.1)               | 5 (16.7)  | 6 (6.5)   | 22 (17.2) | 78 (13.1)   |
| 6–12                       | 45 (13.1)               | 5 (16.7)  | 17 (18.3) | 21 (16.4) | 88 (14.8)   |
| > 12                       | 57 (16.9)               | 8 (26.7)  | 29 (31.2) | 34 (26.6) | 128 (21.5)  |
| BM lesion number           |                         |           |           |           |             |           |
| 1                          | 166 (48.3)              | 11 (36.7) | 25 (26.9) | 36 (28.1) | 238 (40.0)  |
| 2–3                        | 53 (15.4)               | 7 (23.3)  | 18 (19.4) | 22 (17.2) | 100 (16.8)  |
| ≥ 4                        | 125 (36.3)              | 12 (40.0) | 50 (53.8) | 70 (54.7) | 257 (43.2)  |
| Extracranial met.          | 268 (77.9)              | 19 (63.3) | 64 (68.8) | 84 (65.6) | 0.019       | 435 (73.1) |
| Brain stem met.            | 91 (2.4)                | 1 (0.0)   | 3 (3.2)   | 3 (2.3)   | ns          | 16 (2.7)   |
| Meningeal met.             | 25 (7.3)                | 2 (6.7)   | 2 (2.2)   | 9 (7.0)   | ns          | 43 (6.4)   |
| Targeted therapy           | 97 (28.2)               | 9 (30.0)  | 23 (24.7) | 39 (30.5) | ns          | 168 (28.2) |
| Chemotherapy               | 173 (50.3)              | 11 (36.7) | 43 (46.2) | 72 (56.3) | 0.199       | 299 (50.3) |
| SRT                        | 14 (5.1)                | 0 (0.0)   | 0 (0.0)   | 1 (0.8)   | 0.060       | 15 (2.5)   |
| Local/boost RT (Gy)        |                         |           |           |           |             |           |
| none                       | 325 (94.5)              | 23 (76.7) | 15 (16.1) | 55 (43.0) | < 0.001     | 418 (73.0) |
| <50                        | 8 (2.3)                 | 6 (20.0)  | 3 (3.2)   | 6 (4.7)   | 23 (3.9)    |
| 50–59                      | 9 (2.6)                 | 1 (3.3)   | 38 (40.9) | 42 (32.8) | 90 (15.1)   |
| ≥ 60                       | 2 (0.6)                 | 0 (0.0)   | 37 (39.8) | 25 (19.5) | 64 (10.8)   |
| BM resection               |                         |           |           |           |             |           |
| none                       | 326 (94.8)              | 29 (96.7) | 90 (96.8) | 118 (92.2) | ns          | 563 (94.6) |
| incomplete                 | 2 (0.7)                 | 0 (0.0)   | 0 (0.0)   | 2 (1.5)   | 4 (0.7)     |
| complete                   | 16 (4.7)                | 1 (3.3)   | 3 (3.2)   | 8 (6.3)   | 28 (4.7)    |
| Initial cTNM Stage IV      | 274 (79.7)              | 21 (70.0) | 55 (59.1) | 75 (58.6) | < 0.001     | 425 (71.4) |
| Lung tumor surgery         |                         |           |           |           |             |           |
| none                       | 301 (87.5)              | 23 (76.7) | 67 (72.0) | 90 (70.3) | < 0.001     | 481 (80.8) |
| incomplete                 | 6 (1.7)                 | 3 (10.0)  | 4 (4.3)   | 11 (8.6)  | 24 (4.0)    |
| radical                    | 37 (10.8)               | 4 (13.3)  | 22 (23.7) | 27 (21.1) | 90 (15.1)   |

| ns | none | 0.001 | < 0.001 | 0.001 | ns |
survival are rarely studied in NSCLC BM patients alone. These profiles are significantly complicated by factors of age, KPS, tumor type, BM lesion number, extracranial metastatic status, local RT modalities, among others [26]. Through this retrospective multivariable analysis, we found that compared to none, WBRT dose ≥ 30 Gy was invariably associated with improved OS and iPFS. This finding further warrants clinical trials for confirmation. Whether and how the lower WBRT < 30 Gy provide benefits is still unknown and should be further investigated in controlled studies.

This study used a recent large dataset from the real world. Due to differences in healthcare system and socio-cultural reasons, WBRT was administered for only 43% of all NSCLC BM patients newly treated in 2013–2015 at a single cancer institution in China. In this study, patients with WBRT 30–39 and ≥ 40 Gy had estimated MTS of OS of 10.3 and 11.9 months, respectively. Compared to non-WBRT patients, patients with WBRT ≥ 30 Gy had extended MTS of 4.5–6 months. Similar survival results have also been reported in other Chinese studies [27, 28]. Xiang et al. reported that 135 NSCLC BM patients with WBRT-based combined therapies had MTS of OS as 9.3 months, 1-year and 2-year survival rates as 46.3 and 16.1%, respectively [27]. Zhu et al. reported that 29 inoperable NSCLC BM patients treated with WBRT 40 Gy/20f plus simultaneous in-field boost IMRT 20Gy/5f had estimated MTS of OS and of iPFS as both 10 months [28]. Neither of two studies above enrolled non-WBRT patients. In our study, there were 58%

### Table 1 Patient characteristics and their comparison among subgroups by WBRT dose (Continued)

| Variables         | WBRT Dose          | All            |
|-------------------|--------------------|----------------|
|                   | None (< 30Gy)     | < 30Gy (n1 = 344) | 30–39Gy (n2 = 30) | ≥ 40Gy (n3 = 93) | ≥ 40Gy (n4 = 128) | (N = 595) |
| n(%)              | n(%)              | n(%)           | n(%)             |
| Adenocarcinoma    | 242 (70.3)        | 22 (73.3)      | 66 (71.0)        | 91 (71.1)       | ns              | 421 (70.8) |
| EGFR mutation     |                    |                |                  |                 |
| neg.              | 55 (16.0)         | 3 (10.0)       | 23 (24.7)        | 20 (15.6)       | ns              | 101 (17.0) |
| pos.              | 74 (21.5)         | 5 (16.7)       | 13 (14.0)        | 22 (17.2)       | 114 (19.2)      |
| no record         | 215 (62.5)        | 22 (73.3)      | 57 (61.3)        | 86 (67.2)       | 380 (63.9)      |
| ALK mutation      |                    |                |                  |                 |
| neg.              | 15 (4.4)          | 1 (3.3)        | 3 (3.2)          | 3 (2.3)         | 0.069           | 22 (3.7)    |
| pos.              | 1 (0.3)           | 2 (6.7)        | 2 (2.2)          | 1 (0.8)         | 6 (1.0)         |
| no record         | 328 (95.3)        | 27 (90.0)      | 88 (94.6)        | 124 (96.9)      | 567 (95.3)      |

*WBRT* whole brain radiotherapy; CVD cardiovascular disease; ns not significant with *p* > 0.20; BM brain metastasis; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases; SRT stereotactic radiotherapy; RT radiotherapy; EGFR epidermal growth factor receptor; neg. Negative; pos. Positive; ALK anaplastic lymphoma kinase.

* from the Chi-square or Fisher’s exact (if applied) test.

Fig. 1 Kaplan-Meier overall (OS) and intracranial progression-free survival (iPFS) curves respectively (a & b) for the entire cohort of study population by the whole-brain radiation therapy (WBRT) use status. Risk mentioned in the figure titles means the WBRT status.
| Variables                      | OS HR  | 95%CI          | p*  | IPFS HR | 95%CI          | p*  |
|-------------------------------|--------|----------------|-----|---------|----------------|-----|
| **WBRT (Gy)**                 |        |                |     |         |                |     |
| none                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| < 30                          | 1.418  | (0.938–2.142)  | 0.098| 1.713   | (1.133–2.588)  | 0.011|
| 30–39                         | 0.709  | (0.540–0.933)  | 0.014| 0.694   | (0.533–0.904)  | 0.007|
| ≥ 40                          | 0.616  | (0.483–0.785)  | 0.001| 0.640   | (0.506–0.809)  | 0.001|
| **Local/boost RT (Gy)**       |        |                |     |         |                |     |
| none                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| < 50                          | 0.722  | (0.422–1.234)  | ns  | 0.977   | (0.608–1.572)  | ns  |
| 50–59                         | 0.575  | (0.436–0.759)  | 0.001| 0.668   | (0.515–0.866)  | 0.002|
| ≥ 60                          | 0.594  | (0.427–0.825)  | 0.002| 0.566   | (0.409–0.783)  | 0.001|
| **SRT**                       |        |                |     |         |                |     |
| none                          | 0.761  | (0.627–1.391)  | ns  | 0.645   | (0.344–1.208)  | ns  |
| Female                        | 0.970  | (0.801–1.175)  | ns  | 1.039   | (0.863–1.250)  | ns  |
| **Age (years)**               |        |                |     |         |                |     |
| < 50                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| 50–59                         | 1.051  | (0.783–1.412)  | ns  | 0.889   | (0.673–1.174)  | ns  |
| ≥ 60                          | 1.363  | (1.038–1.791)  | 0.052| 1.169   | (0.904–1.512)  | ns  |
| **KPS**                       |        |                |     |         |                |     |
| < 70                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| 70–80                         | 0.920  | (0.718–1.178)  | ns  | 0.918   | (0.722–1.166)  | ns  |
| ≥ 90                          | 0.765  | (0.610–0.958)  | 0.020| 0.842   | (0.676–1.047)  | ns  |
| **NSCLC history (month)**     |        |                |     |         |                |     |
| < 1                           | 0.910  | (0.710–1.167)  | ns  | 1.023   | (0.805–1.299)  | ns  |
| 1–6                           | 1.153  | (0.834–1.595)  | ns  | 1.410   | (1.030–1.931)  | 0.032|
| 6–12                          | 1.107  | (0.799–1.533)  | ns  | 1.236   | (0.972–1.693)  | 0.187|
| > 12                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| **BM lesion number**          |        |                |     |         |                |     |
| 1                             | 1.000  | ref.           |     | 1.000   | ref.           |     |
| 2–3                           | 1.103  | (0.833–1.461)  | ns  | 1.053   | (0.804–1.379)  | ns  |
| ≥ 4                           | 1.118  | (0.907–1.377)  | ns  | 1.099   | (0.898–1.344)  | ns  |
| **Extracranial met.**         |        |                |     |         |                |     |
| 1.244                         | 0.063  | (0.988–1.565)  | 1.695| (1.356–2.120) | 0.001|
| **Brain stem met.**           |        |                |     |         |                |     |
| 2.185                         | 0.008  | (1.226–3.896)  | 1.901| (1.069–3.381) | 0.029|
| **Meningeal met.**            |        |                |     |         |                |     |
| 1.212                         | 0.008  | (0.853–1.723)  | 1.501| (1.063–2.119) | 0.021|
| **Targeted therapy**          |        |                |     |         |                |     |
| 0.492                         | < 0.001| (0.393–0.617)  | 0.597| (0.484–0.736) | < 0.001|
| **Chemotherapy**              |        |                |     |         |                |     |
| 0.612                         | < 0.001| (0.506–0.741)  | 0.791| (0.659–0.951) | 0.013|
| **BM resection**              |        |                |     |         |                |     |
| none                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| incomplete                    | 0.786  | (0.196–3.157)  | ns  | 0.808   | (0.201–3.245)  | ns  |
| complete                      | 0.882  | (0.556–1.398)  | ns  | 0.851   | (0.549–1.320)  | ns  |
| **Initial cTNM Stage IV**     |        |                |     |         |                |     |
| none                          | 1.027  | (0.829–1.271)  | ns  | 1.106   | (0.901–1.357)  | ns  |
| **Lung tumor surgery**        |        |                |     |         |                |     |
| none                          | 1.000  | ref.           |     | 1.000   | ref.           |     |
| incomplete                    | 0.842  | (0.524–1.353)  | ns  | 0.865   | (0.546–1.372)  | ns  |
(n = 344) NSCLC BM patients without WBRT as the analysis control.

Whether and how WBRT improves survivals of BM patients at low dose is a difficult question. Further studies on pathophysiology and radiobiological mechanisms of WBRT on BM are required. Through the most recent Cochrane database systematic review, Tsao et al. concluded that the HR of OS with lower biological WBRT doses as compared with control of 30Gy/10f was 1.21 (1.04–1.40, p = 0.01) and with higher biological WBRT doses vs. 30 Gy/10f was 0.97 (0.83–1.12, p = 0.65); both are regarded to have “moderate-certainty” evidences [20]. In addition to WBRT dose, many other multifactor- ial and interrelated complexes can contribute to survival: such as genetic mutation and blood-brain barrier interactions with local treatments (e.g. RT or surgery) or drugs [20, 26, 27]. Thus far, WBRT administered after local surgery or SRT for patients with 1–3 BM has been evidenced to reduce neurologic death and intracranial relapse but not overall mortality [14, 29]. Currently, many studies have indicated a tendency of longer OS for WBRT-based RT regimens compared to chemotherapeutic ones [18, 20]. However, in the recently published QUARTZ trial, Mulvenna et al. concluded that WBRT provides no better survival than optimal supportive care (OSC) in NSCLC BM patients considered unsuitable for surgical resection or SRT [30]. In this trial, 538 patients in 2007–2014 were randomly assigned into OSC or OSC + WBRT (20Gy/5fr) arms; both arms had the similar MSTs (8.5 and 9.2 weeks, respectively) with an insignificant HR of 1.06 (95 CI 0.90–1.26, p = 0.81) [30]. We noticed that the QUARTZ trial treatment regimens served more palliative than curative purposes and that BM patients were recruited over 8 years and had quite short life expectancy period. Nonetheless, we believe our study population was far more representative of the real world of NSCLC BM patients in recent years and the conclusion should be applicable to the general NSCLC BM patients.

Many trials have failed to define the optimal dose and schedule of WBRT for OS or tumor control [7, 18, 20]. Most of them used various dose-fractionation schedules of WBRT 20–40 Gy/10–20f and had different endpoints making comparison and generalization of the dose-effect profile difficult. Indeed, given that WBRT dose of either 30Gy or 40Gy is biologically regarded to be well below the lethal RT dose (presumably over 50 Gy) of tumor, the majority of WBRT regimens in those trials were intended only for palliative purposes [7, 11, 12, 18]. Two RTOG trials in the early 1970s each enrolling over 900 BM patients had concluded that multiple WBRT sched- ules (low vs. high of 20–40 Gy) and time periods (short vs. long of 2 to 4 weeks) had similar tumor response rate, palliative effects, and time to progression and survival [11]; randomly-added ultra-short WBRT schedules (10Gy/1f vs. 12Gy/2f vs. 20Gy/5f) led to the same survival time but shorter time to brain tumor progression [12]. Kurtz et al. conducted one randomized control trial (RCT) in 255 highly-selected BM patients with good prognosis to conclude that WBRT 50Gy/20f and 30Gy/ 10f schedules had similar effects of symptom palliation, time to progression, cause of death, and survival [31]. Another trial comparing WBRT 32Gy plus 24.4 Gy to a boost field in 1.6 Gy fractions (b.i.d.) with WBRT 30Gy/ 10f among 445 patients had demonstrated that the accelerated hyper-fraction of WBRT made no difference on survival time [32]. However, one trial indicated that WBRT 40Gy/20f (b.i.d) in 113 patients had similar OS but higher tumor control rate (56% vs. 36%) and lower neurological mortality (32% vs. 52%, p = 0.03) than

| Variables | OS | iPFS |
|-----------|----|------|
|           | HR | 95%CI | p<sup>a</sup> | HR | 95%CI | p<sup>a</sup> |
| radical   | 0.917 | (0.687–1.225) | ns | 0.695 | (0.527–0.916) | 0.001 |
| Adenocarcinoma | 0.809 | (0.659–0.993) | 0.043 | 0.821 | (0.672–1.002) | 0.053 |
| EGFR mutation |               |            |      |     |      |          |
| neg.      | 1.000 | ref. | ref. | 1.000 | ref. | ref. |
| pos.      | 0.670 | (0.484–0.927) | 0.016 | 0.625 | (0.460–0.850) | 0.003 |
| no record | 1.195 | (0.931–1.534) | 0.161 | 0.962 | (0.756–1.226) | ns |
| ALK mutation |               |            |      |     |      |          |
| neg.      | 1.000 | ref. | ref. | 1.000 | ref. | ref. |
| pos.      | 0.415 | (0.118–1.458) | 0.170 | 1.059 | (0.351–3.191) | ns |
| no record | 1.006 | (0.578–1.750) | ns | 1.109 | (0.663–1.857) | ns |

**Table 2** Univariate Cox model analyses (Continued)

**Notes:**
- OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; WBRT whole brain radiotherapy; ref. reference; RT radiotherapy; ns not significant with p > 0.20; SRT stereotactic radiotherapy; CVD cardiovascular disease; BM brain metastasis; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases; EGFR epidermal growth factor receptor; pos. Positive; neg. Negative; ALK anaplastic lymphoma kinase.
- From the univariate Cox model analysis.
Table 3  Multivariable Cox model analyses

| Variables                   | OS |         |         |         |         |         |         |         |
|-----------------------------|----|---------|---------|---------|---------|---------|---------|---------|
|                             | HR | 95%CI   | p*      | HR      | 95%CI   | p*      | HR      | 95%CI   | p*      |
| WBRT (Gy)                   |    |         |         |         |         |         |         |         |         |
| none                        | 1.00| ref.   |        | 1.00| ref. |        |        |        |         |
| < 30                        | 1.227| (0.787–1.914)| ns   | 1.625| (1.045–2.528)| 0.031 |        |        |         |
| 30–39                       | 0.722| (0.500–1.042)| 0.082 | 0.714| (0.502–1.017)| 0.062 |        |        |         |
| ≥ 40                        | 0.609| (0.453–0.818)| 0.007 | 0.669| (0.500–0.895)| 0.007 |        |        |         |
| Local/boost RT (Gy)         |    |         |         |         |         |         |         |         |         |
| none                        | 1.00| ref.   |        | 1.00| ref. |        |        |        |         |
| < 50                        | 0.609| (0.341–1.088)| 0.042 | 0.930| (0.555–1.561)| ns    |        |        |         |
| 50–59                       | 0.572| (0.402–0.815)| 0.003 | 0.776| (0.551–1.092)| 0.146 |        |        |         |
| ≥ 60                        | 0.580| (0.385–0.873)| 0.019 | 0.641| (0.427–0.963)| 0.032 |        |        |         |
| SRT                         | 0.653| (0.326–1.308)| 0.022 | 0.708| (0.364–1.376)| ns    |        |        |         |
| Female                      | 0.798| (0.644–0.988)| 0.039 | 0.804| (0.655–0.987)| 0.037 |        |        |         |
| CVD                         | 0.868| (0.706–1.068)| 0.182 | 0.936| (0.765–1.145)| ns    |        |        |         |
| Age (years)                 |    |         |         |         |         |         |         |         |         |
| < 50                        | 1.00| ref.   |        | 1.00| ref. |        |        |        |         |
| 50–59                       | 1.089| (0.799–1.486)| ns   | 0.854| (0.638–1.142)| ns    |        |        |         |
| ≥ 60                        | 1.335| (0.990–1.800)| 0.058 | 1.088| (0.820–1.444)| ns    |        |        |         |
| KPS                         |    |         |         |         |         |         |         |         |         |
| < 70                        | 1.00| ref.   |        | 1.00| ref. |        |        |        |         |
| 70–80                       | 0.987| (0.762–1.279)| ns   | 0.964| (0.748–1.241)| 0.774 |        |        |         |
| ≥ 90                        | 0.620| (0.479–0.801)| 0.000 | 0.670| (0.521–0.862)| 0.002 |        |        |         |
| NSCLC history (month)       |    |         |         |         |         |         |         |         |         |
| < 1                         | 0.632| (0.473–0.844)| 0.002 | 0.780| (0.595–1.023)| 0.072 |        |        |         |
| 1–6                         | 0.895| (0.626–1.280)| ns   | 1.249| (0.891–1.750)| 0.197 |        |        |         |
| 6–12                        | 0.741| (0.525–1.045)| 0.087 | 0.828| (0.590–1.160)| ns    |        |        |         |
| > 12                        | 1.000| ref.   |        | 1.000| ref. |        |        |        |         |
| BM lesion number            |    |         |         |         |         |         |         |         |         |
| 1                           | 1.000| ref.   |        | 1.000| ref. |        |        |        |         |
| 2–3                         | 1.181| (0.870–1.602)| ns   | 1.023| (0.766–1.366)| ns    |        |        |         |
| ≥ 4                         | 1.325| (1.045–1.681)| 0.020 | 1.148| (0.911–1.447)| ns    |        |        |         |
| Extracranial met.           | 1.313| (1.019–1.691)| 0.035 | 1.836| (1.428–2.361)| 0.000 |        |        |         |
| Brain stem met.             | 1.219| (0.664–2.235)| ns   | 1.009| (0.548–1.857)| ns    |        |        |         |
| Meningeal met.              | 0.935| (0.633–1.382)| ns   | 1.136| (0.772–1.670)| ns    |        |        |         |
| Targeted therapy            | 0.373| (0.290–0.480)| 0.000 | 0.506| (0.402–0.636)| 0.000 |        |        |         |
| Chemotherapy                | 0.587| (0.476–0.724)| 0.000 | 0.724| (0.592–0.885)| 0.002 |        |        |         |
| BM resection                |    |         |         |         |         |         |         |         |         |
| none                        | 1.000| ref.   |        | 1.000| ref. |        |        |        |         |
| incomplete                  | 0.834| (0.200–3.482)| ns   | 0.854| (0.206–3.532)| ns    |        |        |         |
| complete                    | 0.709| (0.429–1.171)| 0.180 | 0.909| (0.557–1.486)| ns    |        |        |         |
| Lung tumor surgery          |    |         |         |         |         |         |         |         |         |
| none                        | 1.000| ref.   |        | 1.000| ref. |        |        |        |         |
| incomplete                  | 0.889| (0.533–1.482)| ns   | 0.911| (0.559–1.483)| ns    |        |        |         |
| radical                     | 0.773| (0.553–1.080)| 0.132 | 0.705| (0.508–0.978)| 0.036 |        |        |         |

OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; WBRT whole brain radiotherapy; ref. reference; ns not significant with p > 0.20; RT radiotherapy; SRT stereotactic radiotherapy; CVD cardiovascular disease; BM brain metastases; KPS Karnofsky Performance Score; NSCLC non-small cell lung cancer; met. Metastases.

* from the multivariable Cox model analysis.
WBRT 20Gy/4f, [33]. Another trial involving 533 patients showed that WBRT 30Gy/10f compared to WBRT 12Gy/2f had a slight but statistically better OS ($p = 0.04$) [10]. These trials support our conclusion that WBRT doses $\geq 30$ Gy provide better intracranial tumor control.

How the local treatment of BM (surgery, SRT or boost RT) impacts the dose-effect survival profiles of WBRT is infrequently studied. Some published trials showed that combining SRT or surgery with fixed-dose-schedule of WBRT had improved OS and reduced local failure in

| BM Lesions | WBRT (Gy) | OS HR | 95%CI | $p^a$ | iPFS HR | 95%CI | $p^a$ |
|------------|-----------|-------|-------|---------|---------|-------|--------|
| 1–3 (N1 = 338) | none | 1.000 | ref. | 1.000 | ref. |
| < 30 | 1.607 | (0.876–2.946) | 0.125 | 1.660 | (0.915–3.009) | 0.095 |
| 30–39 | 0.781 | (0.432–1.413) | ns | 0.700 | (0.408–1.201) | 0.196 |
| $\geq 40$ | 0.639 | (0.403–1.012) | 0.056 | 0.592 | (0.380–0.924) | 0.021 |
| $\geq 40$ vs. 30–39 (ref.) | 0.818 | (0.456–1.466) | 0.499 | 0.846 | (0.505–1.417) | 0.526 |

| 4+ (N2 = 257) | none | 1.000 | ref. | 1.000 | ref. |
| < 30 | 0.977 | (0.487–1.957) | ns | 1.880 | (0.915–3.863) | 0.086 |
| 30–39 | 0.589 | (0.348–0.996) | 0.048 | 0.699 | (0.421–1.159) | 0.165 |
| $\geq 40$ | 0.514 | (0.328–0.806) | 0.004 | 0.624 | (0.401–0.969) | 0.036 |
| $\geq 40$ vs. 30–39 (ref.) | 0.873 | (0.540–1.413) | 0.581 | 0.892 | (0.558–1.426) | 0.634 |

BM brain metastases; WBRT whole brain radiotherapy; OS overall survival; iPFS intracranial progression-free survival; HR hazard ratio; 95%CI 95% confidence interval; ns not significant with $p >0.20$; ref. reference

$^a$ from the multivariable Cox model analysis without BM lesion group as one covariate

Table 5 Prognostic index adjusted Cox models

| Prognostic Index | n (% | OS MTS | Univariate | Prognostic Index & RT modality$^a$ adjusted |
|-----------------|-------|---------|------------|---------------------------------------------|
| RPA class       |       |         | HR | $p^b$ | HR | $p^c$ | WBRT (Gy) | HR | $p^c$ |
| I               | 18 (3)| 14.1    | 0.039 | 0.435 | 0.322 | 0.545 | 0.122 | none | 1.000 | ref. |
| II              | 387 (65)| 9.5 | 0.839 | 0.094 | 0.703 | 0.001 | < 30 | 1.412 | 0.120 |
| III             | 190 (32)| 8.7 | 1.000 | ref. | 1.000 | ref. | 30–39 | 0.969 | 0.861 |
| Lung-GPA score  |       |         |     |       |       |       |       |       |       |
| 0–1.0           | 217 (36)| 8.3 | 0.001 | 1.000 | ref. | 1.000 | ref. | none | 1.000 | ref. |
| 1.5–2.0         | 244 (41)| 8.5 | 0.935 | 0.528 | 0.910 | 0.387 | < 30 | 1.497 | 0.072 |
| 2.5–3.0         | 117 (20)| 13.0 | 0.615 | 0.001 | 0.580 | 0.000 | 30–39 | 0.919 | 0.644 |
| 3.5–4.0         | 17 (3)| 17.2 | 0.478 | 0.031 | 0.511 | 0.051 | $\geq 40$ | 0.731 | 0.023 |
| Lung-molGPA score |       |         |     |       |       |       |       |       |
| 0–1.0           | 169 (28)| 7.0 | 0.000 | 1.000 | ref. | 1.000 | ref. | none | 1.000 | ref. |
| 1.5–2.0         | 289 (49)| 8.9 | 0.715 | 0.002 | 0.629 | 0.000 | < 30 | 1.673 | 0.026 |
| 2.5–3.0         | 126 (21)| 12.7 | 0.521 | 0.000 | 0.453 | 0.000 | 30–39 | 0.890 | 0.516 |
| 3.5–4.0         | 11 (2)| 25.0 | 0.259 | 0.008 | 0.186 | 0.001 | $\geq 40$ | 0.697 | 0.009 |
| $\geq 40$ vs. 30–39 | 0.845 | 0.342 |

OS overall survival; RT radiotherapy; MTS median survival time in months; WBRT whole brain radiotherapy; HR hazard ratio; ref. reference; RPA the recursive partitioning analysis; GPA the graded prognostic assessment; Lung-GPA the lung cancer-specific GPA; Lung-molGPA the lung cancer-specific GPA using molecular markers.

$^a$RT modalities included WBRT, local/boost RT and SRT.

$^b$from the log-rank test.

$^c$from the Cox model test.
patients with single metastasis only [16, 34]. Andrews et al. conducted one RCT of 333 patients with 1–3 BM lesions and found that compared to WBRT alone, SRS + WBRT (37.5Gy/15f) had a better local control rate at 1 year follow-up (82% vs. 71%, p = 0.01) and better OS for single metastasis patients only (MTS 6.5 vs. 4.9 months, p = 0.04) but not in the entire cohort (6.5 vs. 5.7 months, p = 0.14); for NSCLC BM patients only, their MTS of ‘SRS + WBRT’ and ‘WBRT alone’ patients were estimated as 5.0 vs. 3.9 months (p = 0.05), respectively [16]. Patchell et al. conducted another RCT by assigning 48 patients with single BM into surgery + WBRT (36 Gy/12f) vs. WBRT alone and found significant advantages of lower local failure (20% vs. 52%, p < 0.02) and longer MTS (40 weeks vs. 15 weeks, p < 0.01) for the surgery + WBRT patients [34]. However, one trial by Mintz et al. failed to show the benefit of improving OS (MST 5.6 months vs. 6.3 months, p = 0.24) by having surgery first for the single BM patients who had the universal WBRT 30Gy/10f [35]. To determine the effects of adding boost RT to WBRT, Antoni et al. retrospectively analyzed 208 BM patients (137 from lung cancer) with RPA II and 1–2 metastases and found that patients with boost RT 9Gy/3f had MST of 2.2 months longer (5.9 vs. 3.7 months, p = 0.03) and higher local tumor control rates at 6-, 12- and 24-month (p = 0.03) than patients with WBRT (30Gy/10f) alone [36]. In this study, we had 15 SRT patients (only one had subsequent WBRT) and 32 surgical patients (14 of them had WBRT before or after BM surgery). Through multivariable analyses, we found that SRT was associated with better OS but not iPFS, and the boost ≥50 Gy was associated with better OS than iPFS (Table 3).

Other factors affecting OS and iPFS were also identified in this study. Chemotherapy and targeted therapy were found to be quite effective in improving OS and iPFS (p < 0.001). While female, young age, good KPS, short NSCLC history, and primary tumor resection were associated with improved survival, the presence of extracranial metastasis and BM lesions ≥4 predicted poorer survival. These findings were consistent with other studies [4, 37–42]. In this study, instead of using calculated GPA or RPA score, we decided to use individual covariates in Cox models to better estimate the independent dose-survival effect of WBRT. The adjustment analyses by RPA, Lung-GPA or Lung-molGPA confirmed that OS and iPFS profiles of WBRT dose level have not changed. The survival profiles of these common prognostic indices were also found to be consistent with other studies [4, 6, 41].

We recognize that our current study has both limitations and strengths. In addition to the hidden selection biases of any retrospective analysis, weaknesses include: (1) the resultant link of delivered ‘RT boost’ and higher WBRT dose could compromise their independent benefit profile evaluation in somewhat way even through multivariate and stratified analyses; (2) the BED of WBRT was not calculated for use; we were concerned with the accuracy and validity of using traditional linear-quadratic formula and citing a specific α/β value for BED calculation among these NSCLC BM patients who received heterogeneous modalities of RT rather than the fixed-schedule of universal WBRT; as aforementioned, the actual percents of 40Gy/20f, 30Gy/10f, and 37.5Gy/15f regimen used were 46, 41, and 5% in 251 WBRT patients; (3) neither neurologic symptoms nor quality of life measurements were collected; (4) Only 4.7% of patients took the ALK gene mutation test; how this low test rate, high positive rate (21%, 6/28) and the rare use of ALK drugs in the Chinese population impact the study results was difficult to assess. Strengths of this study include (1) our cohort study was conducted at a single center between 2013 to 2015 during which the guidelines of NSCLC BM treatment experienced little variation; (2) three other RT modalities in their independent formats were considered in multivariable analyses; (3) individual covariates were also presented in the final models.

Conclusions

We conclude that compared to none, WBRT’ doses ≥30 Gy are invariably associated with improved intracranial tumor control and survival in NSCLC BM patients.

Abbreviations

ALK: Anaplastic lymphoma kinase; BED: Biological effective dose; BM: Brain metastases; CI: Confidence interval; CVD: Cardiovascular disease; EGFR: Epidermal growth factor receptor; f: Fractions; GPA: Graded prognostic assessment; HR: Hazard Ratio; IMRT: Intensity-modulated radiotherapy; iPFS: Intracranial progression-free survival; KPS: Karnofsky Performance Score; MST: Median survival time; NSCLC: Non-small cell lung cancer; OS: Overall survival; OSC: Optimal supportive care; RT: Radiotherapy; SAE: Serious adverse events; SRT: Stereotactic radiotherapy; std.: Standard deviation; WBRT: Whole brain radiotherapy

Acknowledgements

The authors would like to offer special thanks to all clinical staff who worked at the Fourth Hospital of Hebei Medical and provided years of clinical care for these patients with brain metastases enrolled in this study.

Ethic approval and consent to participate

The study was approved by the Medical Ethics Committee of the Fourth Hospital of Hebei Medical University in China in 2016. No written or verbal consent from all participants was needed under the Chinese government’s medical research regulations given the study design was a retrospective analysis and only de-identified health information was used.

Authors’ contributions

ZL was principally responsible for study design, data collection, analysis and article writing. DS was responsible for data collection and quality control and contributed to the analysis. JiZ and JuZ managed the overall study and revised the manuscript. FY, DK, JK and AZ contributed to the analysis and discussion. All authors read and approved the final manuscript.

Funding

none.
References

1. Goncalves PH, Peterson SL, Vigneau FD, et al. Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the metropolitan Detroit surveillance, epidemiology, and end results (SEER) data. Cancer. 2016;122(12):1921–7. https://doi.org/10.1002/cncr.30000.
2. Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer. 2007;109:1668–75.
3. Weissman DE. Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol. 1988;6(3):543–51.
4. Gaspar L, Scott C, Rotman M. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–51.
5. Sundstrom JF, Minn H, Lertoila KK, et al. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med. 1998;30(3):296–9.
6. Sperduto PW, Kasid N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(6):619–25.
7. Scorciari S, Ricardi U. Treatment of brain metastases: review of phase II randomized controlled trials. Radiother Oncol. 2012;102(2):168–79. https://doi.org/10.1016/j.radonc.2011.08.041.
8. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295–304.
9. Tsao MN, Rades D, With A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2(3):210–25. https://doi.org/10.1016/j.prro.2011.12.004.
10. Priezman TJ, Dunn J, Brada M, et al. Final results of the Royal College of Radiologists’ trial comparing two different radiotherapy schedules in the treatment of cerebral metastasis. Clin Oncol (R Coll Radiol). 1996;8:308–15.
11. Borget B, Geller R, Kramer S. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1980;6:1–9.
12. Borget B, Geller R, Larson M, et al. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1981;7:1633–8.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers, Version 2.2018. Available at http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf.
14. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.
15. Rades D, Bohlen G, Pluemner A, et al. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer. 2007;109(12):2515–21.
16. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.
17. Churilla TM, Ballman KV, Brown PD, et al. Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the north central Cancer treatment group N0574 (Alliance) randomized controlled trial. Int J Radiat Oncol Biol Phys. 2017;99(5):1173–8. https://doi.org/10.1016/j.ijrobp.2017.07.045.
18. Peters S, Bexellus C, Munk V, et al. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–62. https://doi.org/10.1016/j.ctrv.2016.03.009.
19. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 2009;10(11):1037–44.
20. Tsao MN, Xu W, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2018;1:CDO03869. https://doi.org/10.1002/14651858.CD003869.pub4.
21. Monaco EA 3rd, Faraji AH, Berkowitz O, et al. Leukoencephalopathy after whole-brain radiotherapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer. 2013;119(12):226–32. https://doi.org/10.1002/cncr.27504.
22. Lee SM, Lewanski CR, Counsell N. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst. 2014;106:dju151.
23. Mehta MP, Shapiro WR, Phan SC. Motexafin golinum combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys. 2009;73:1069–76.
24. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–6. https://doi.org/10.1200/JCO.2014.57.2909.
25. Harth S, Abo-Madyan Y, Zheng L, et al. Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. Radiat Oncol. 2013;19(1):152–8. https://doi.org/10.1186/1748-717X-9-152.
26. Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33:3475–84.
27. Xiang Z, Chen J, Zhang H, et al. Whole brain radiotherapy-based combined modality treatment of brain metastases from non-small cell lung cancer: a retrospective analysis of prognostic factors. Oncol Res Treat. 2015;38(1–2):35–40. https://doi.org/10.1159/000371501.
28. Zhou L, Liu J, Xue J, et al. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer. Radiat Oncol. 2014;9(117). https://doi.org/10.1186/1748-717X-9-117.
29. Kocher M, Soffritti R, Abacioglu U, et al. Adjunctive whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134–41.
30. Mulvanna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ2): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14. https://doi.org/10.1016/S0140-6736(16)30825-X.
31. Kurtz JM, Geller B, Brady LW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1981;7(7):891–5.
32. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the radiation therapy oncology group (RTOG) 9104. Int J Radiat Oncol Biol Phys. 1997;39(3):571–4.
33. Graham PH, Bucci J, Browne L. Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases. Int J Radiat Oncol Biol Phys. 2010;77(3):848–54. https://doi.org/10.1016/j.ijrobp.2009.05.032.
34. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.
35. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470–6.
36. Antoni D, Glaeter JB, Pop M, et al. 3D radiotherapy boost improves the outcome of whole brain radiation therapy treated RPA II patients with one or two brain metastases. Int J Mol Sci. 2014;15(5):7554–62.
37. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91(4):710–7. https://doi.org/10.1016/j.ijrobp.2014.10.024.
38. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):71–83. https://doi.org/10.1007/s11060-009-0062-7.

39. Rades D, Schild SE, Lohynska R, et al. Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer. 2007;110:1077–82.

40. Sperduto PW, Chao ST, Sneed PK. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655–61.

41. Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 2017;3(6):827–31. https://doi.org/10.1001/jamaoncol.2016.3834.

42. Sperduto PW, Yang TJ, Beal K, et al. The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys. 2016;96(2):406–13. https://doi.org/10.1016/j.ijrobp.2016.06.006.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.